Medpace Holdings Inc. (MEDP)
Why Medpace (MEDP) Dipped More Than Broader Market Today
In the most recent trading session, Medpace (MEDP) closed at $561.65, indicating a -1.27% shift from the previous trading day.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
In the latest trading session, Medpace (MEDP) closed at $568.36, marking a +1.45% move from the previous day.
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Here is how Medpace (MEDP) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Medpace (MEDP) Upgraded to Strong Buy: What Does It Mean for the Stock?
Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates
Medpace (MEDP) came out with quarterly earnings of $3.86 per share, beating the Zacks Consensus Estimate of $3.5 per share. This compares to earnings of $3.01 per share a year ago.
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
Medpace (MEDP) concluded the recent trading session at $521.21, signifying a +1.34% move from its prior day's close.
Will Medpace (MEDP) Beat Estimates Again in Its Next Earnings Report?
Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Here is how Medpace (MEDP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace (MEDP) closed at $536.17 in the latest trading session, marking a -1.42% move from the prior day.
Medpace: Profit Margin, Growth, And Repurchase Program Will Trump Legislative Headwinds (Rating Upgrade)
For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. From 2019 to Q2 2025, Medpace's outstanding common shares declined by 22.16%, creating value for its investors. In the first half of 2025, the company had a capex-to-revenues ratio of 1.39%, which contributed to the company's high net profit margin.
Medpace (MEDP) Is Up 5.41% in One Week: What You Should Know
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
